The Company controls approximately s306 issued patent (including 66 for DPCs; 25 for hydrodynamic gene delivery; 26 for pH labile molecules; 7 for polyampholyte; 5 for template polymerization; 12 for delivery polymers; 133 for RNAi trigger molecules; 1 for targeting molecules; 1 for liver expression vector; and 29 for Homing Peptides), including European validations, and 247 patent applications (108 applications in 13 families for DPCs; 140 applications in 23families for RNAi trigger targets; and 8 for Homing Peptides). The pending applications have been filed throughout the world, including, in the United States, Argentina, ARIPO (Africa Regional Intellectual Property Organization), Australia, Brazil, Canada, Chile, China, Eurasian Patent Organization, Europe, Hong Kong, Israel, India, Indonesia, Iraq, Jordan, Japan, Republic of Korea, Mexico, New Zealand, OAPI (African Intellectual Property Organization), Peru, Philippines, Russian Federation, Saudi Arabia, Singapore, Thailand, Taiwan, Venezuela, Vietnam, and South Africa.
Chris Anzalone, Ph.D., president and CEO of Arrowhead Pharmaceuticals, said: ?These data are exciting for several reasons. First, they represent continued progress in our SQ delivery platform, creating opportunities to address various diseases that require chronic treatment and where SQ administration may be preferable for patients and physicians. We are enabling very deep target gene knockdown with long duration of effect that may enable monthly, bi-monthly, or even less frequent administration. Second, reducing Lp(a), as we have seen now in multiple animal models, could represent an important leap forward in the treatment of cardiovascular disease. High levels of Lp(a) are associated with increased risk of cardiovascular disease independent of cholesterol and LDL, and there is currently no good way to deeply reduce circulating levels of Lp(a).?
Let's take a closer look at that concept. We have believed for some time that once we build out our discovery and development capabilities and gain clinical validation for our various technology platforms, we will enter a period marked by rapid pipeline expansion. We are in that period now. Because of the versatility of our technologies, there are substantially more opportunities than we can support independently. And this is a natural part of the growth process for a platform company.
We anticipated that this time would come. And over the last few quarters, we made a strategic shift to seek preclinical discovery-stage development partnerships that could expand the reach of our technologies in areas that are outside of our core focus or beyond our current capabilities and financial resources. In order to attract the highest quality partners, we have also selectively grown our headcount across key departments and will move to a larger research and development facility before year end that will allow us to grow rapidly. With our robust and versatile drug discovery and development engine, we now see Arrowhead as a partner of choice for companies interested in expanding into RNAi therapeutics.
We have said on conference calls this year that we believe we have access to capital through a variety of sources. This continues to be true; and, in fact, we are in active discussions around preclinical discovery-stage collaborations. Of course we cannot predict or provide guidance on the timing or magnitude of these types of agreements or guarantee that they will come to fruition. But they are a focus for us and represent an important part of our ongoing financing strategy.
Arrowhead Pharmaceuticals Closes $45 Million Private Offering
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it closed a previously announced private offering with a select group of investors including Orbimed, RA Capital Management, Perceptive Advisors, RTW Investments and certain other institutional investors. Gross proceeds were $45 million. Approximately 7.63 million shares of common stock were issued at a price of $5.90 per share.
Cantor Fitzgerald & Co. acted as sole placement agent for the private offering. Trout Capital LLC and Chardan Capital Markets LLC acted as financial advisors.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any offer, solicitation or sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. http://ir.arrowheadpharma.com/releasedetail.cfm?ReleaseID=984207
auch die anderen "RNAI-Player" sind dramatisch abgeschmiert,allen voran Galena Biopharma,aber auch Arbutus und Alnylam,erweist sich hier eine einst hochgejubelte neue Technologie wieder mal als rohrkrepierer,so wie bei der warscheinlich auch nicht funkionierenden Stammzelltherapie ?
"Rrowhead sagt, dass es keine Diskussionen über eine mögliche Transaktion gab. Vorstandsvorsitzender Chris Anzalone: ??"Wir konzentrieren uns weiterhin darauf, unsere Programme auf eine Weise zu maximieren, die den Aktionärswert maximiert." Während wir Silence als Aktionär begrüßen, ändert unsere kürzlich angekündigte Beteiligung an Arrowhead unsere Fokus- oder strategischen Pläne in keiner Weise. "
Also für mich klingt das weiter drin bleiben n.m.m :))